PAREXEL INTERNATIONAL (IRL) LIMITED

Parexel International (Irl) Limited is a leading clinical research organisation that partners with biopharmaceutical companies to bring new medicines from early-stage discovery through to market approval. As a dedicated CRO, Parexel offers the full spectrum of Phase I-IV clinical development services, combining deep regulatory knowledge with therapeutic expertise across a wide range of indications, including neuroscience, oncology, cell and gene therapy, endocrine and metabolic disorders.

The company's patient-first philosophy underpins every trial, with specialised neuroscience teams designing studies that balance scientific rigour, market-access considerations and the lived experience of patients. Advanced modelling and simulation tools help predict drug effects early, while a global network of sites accelerates study start-ups and ensures diverse patient recruitment. Parexel's senior experts, such as the Global Neuroscience Therapeutic Area Head, work closely with sponsors to craft efficient development strategies and deliver results quickly and safely.

With more than 24,000 professionals worldwide, Parexel leverages its scale and collaborative culture to turn innovative therapies into real-world treatments, improving outcomes for patients everywhere.